Therefore, to evaluate whether the expression of the Carmil2QE mutation in and only in CD8+ T cells sufficed to mount protective anticancer responses, we analyzed the growth of the syngeneic MC38-OVA colon adenocarcinoma tumor transplanted subcutaneously into WT mice with or without adoptive transfer of OT-I or OT-I Carmil2QE naive T cells. The gene discussed is CD8A; the disease is neoplasm.